Orders by weight:
- B cell deficient mice are useful for basic mechanistic studies of immunologic mechanisms as well as host mice in syngeneic tumor studies using immunogenic test articles.
- Carries a deletion of the endogenous murine J segments of the Ig heavy chain locus.
- In homozygotes, all four JH gene segments are absent, resulting in cells that cannot produce a complete, recombined version of the variable region of the heavy chain.
- B cell development halts at the pro-B cell stage without pre-B cell or mature B cells in the bone marrow. There are significantly fewer B220+ cells in spleen, which are exclusively pro-B cells without IgD. See Phenotypic Data section below.
- This model is expected to have normal T cell development based on published data from a similar model on the BALB/c background.
- For use in syngeneic experiments, this model is on the C57BL/6NTac background and will successfully engraft cell lines of C57BL/6 origin.
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
See the Related Taconic Biosciences Insight:
Genetic Background: C57BL/6NTac Background
The Jh (C57BL/6) mouse was developed by Taconic Biosciences. The model was created through CRISPR/Cas9-mediated gene editing to delete the entire Igh-J locus including all four transcripts. Targeting occurred in C57BL/6NTac embryos. The selected G1 founder was screened for off-target effects and the targeted locus was sequenced to confirm targeting specificity. Heterozygous animals were intercrossed to generate homozygous mice. The line is maintained by crossing homozygous mice.
Genetics: Wild type for Nnt mutation
There is no specific publication describing the generation of these mice, but multiple publications exist demonstrating applications using a similar model on the BALB/c background (Taconic model #1147). See reference list.Other Publications:
Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, Lo KM. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018 Jan 17;10(424):eaan5488
Xu C, Zhang Y, Rolfe PA, Hernández VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H, Yu H, Tighe R, Lo KM, English JM, Radvanyi L, Lan Y. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clin Cancer Res. 2017 Oct 1;23(19):5869-5880
Smith KM, Rahman RS, Spencer LA. Humoral Immunity Provides Resident Intestinal Eosinophils Access to Luminal Antigen via Eosinophil-Expressed Low-Affinity Fcγ Receptors. J Immunol. 2016 Nov 1;197(9):3716-3724